BKd Produces Robust Responses in Relapsed/Refractory Multiple Myeloma

Key Details from the Text about the BKd (Belantamab Mafodotin, carfilzomib, and dexamethasone) Treatment:

Here’s a breakdown of the vital details regarding the BKd treatment, as presented in the text:

1. Efficacy:

* for whom: Patients wiht relapsed/refractory multiple myeloma who have received 1-3 prior lines of treatment.
* Overall Response Rate (ORR): 83%
* Median Progression-Free Survival (PFS): 22.6 months
* The treatment ⁢is effective even in patients who have already undergone multiple prior therapies (2 or 3 lines).

2. Treatment Design (BelaCarD Trial):

* Type: Open-label, single-arm trial.
* Drugs & Dosage:

* Belantamab Mafodotin: 2.5 mg/kg IV on day 1 of cycle 1, then⁣ every second cycle.
* Carfilzomib: 20 mg/m² IV on day⁣ 1 of cycle 1, then 70 mg/m² on ⁣days ⁤1, 8, and 15⁤ of subsequent cycles.
* Dexamethasone: 40 mg orally (20mg for patients >75 years) weekly on days 1,8,15,and 22 of each cycle.
* Cycles: alternating‍ 28-day cycles.
* Safety Run-in: A phased approach to ensure safety,⁣ with dose adjustments based on toxicity levels in the initial patients.
* Primary Endpoint: PFS
*⁢ Secondary Endpoints: ORR,Overall Survival (OS),minimal residual disease,and safety.

3.Safety Profile:

* Adverse Effects (AEs): Very common.
* Any-grade aes: 98%
* Therapy-related AEs: 91%
⁤ * Grade 3 or higher AEs: 87%
* Discontinuation: 25% of patients discontinued treatment ⁤due to AEs.
* ⁢ Dose Adjustments: Frequent dose delays (47%) and reductions (60%).
* Serious AEs: 71% 4% therapy-related.
* Common Any-Grade AEs: nausea (35.71%), Fatigue⁢ (34.29%), Diarrhea (30.00%),Insomnia (27.14%), Vomiting (25.71%).
* Common Grade⁣ 3+ AEs: Hypertension (14.29%), Insomnia (12.86%), Acute Kidney Injury (8.57%).
* Hematologic/Infectious AEs: Upper respiratory tract infection (54%), COVID-19 (28%), ⁢Thrombocytopenia (35%). Grade 3+ included Thrombocytopenia (24%), Lower respiratory tract infection (14%), Anemia (10%), and Sepsis (10%).
* ‍ ⁤ Ocular AEs: Very‍ common ⁣and ofen severe.
* Corneal findings (100%)
* ‍ Visual acuity changes (98%)
⁢* ⁣ Blurred vision (50%)
⁢ * Grade 3 severity in a significant portion of patients (Corneal: 51%,Visual Acuity: 37%,Blurred Vision:⁢ 13%).

In summary: BKd shows⁢ promising efficacy in⁤ patients with relapsed/refractory multiple myeloma, but it is associated with a high rate of adverse events, particularly ocular and hematologic issues, requiring careful monitoring and management.